DDInter856 DDInter1347
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.[A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.
Oritavancin {u} (Compound) resembles {v} (Compound) Telavancin
Oritavancin {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Oritavancin {u} (Compound) causes {v} (Side Effect) Leukocytoclastic vasculitis
Oritavancin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Oritavancin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Oritavancin (Compound) resembles Telavancin (Compound)
Oritavancin (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Oritavancin (Compound) causes Leukocytoclastic vasculitis (Side Effect)
Oritavancin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib